NewsRoom Articles - BioMedWire (BMW)

ThursdayMay 08, 2025 10:00 am

Eye Exam Could Help in Detecting Parkinson’s Disease Early, Study Suggests

New research suggests that a simple examination of the retina could provide an early diagnosis of Parkinson’s disease. Universite Laval researchers conducted this study and their findings appeared in the Neurobiology of Disease journal. According to the researchers, the retinas of individuals having Parkinson’s don’t respond in the same way to light stimulus as those of individuals without the disease. Prof. Martin Levesque, the study leader, explains that currently, people are only diagnosed with Parkinson’s after consulting their doctor regarding tremors and other motor problems. By this time, Levesque adds, the disease has progressed to such an extent that central…

WednesdayMay 07, 2025 10:30 am

Intelligent Bio Solutions Inc. (NASDAQ: INBS) Is ‘One to Watch’

INBS offers a patented, non-invasive testing solution positioned to disrupt a global drug screening market projected to reach $14.9 billion by 2030. The company is revenue-generating, with 148% year-over-year growth in FY 2024 and 450+ active customer accounts. Its Intelligent Fingerprinting system provides rapid, on-site results with a lower cost and higher convenience compared to traditional methods. The Intelligent Fingerprinting Drug Screening System is already in commercial use internationally, and a U.S. product launch is planned for 2025, with FDA 510(k) clearance in process and new patent protections underway. INBS is led by a seasoned executive team with global healthcare…

TuesdayMay 06, 2025 10:00 am

Study: Women with Lung Cancer Have Worse Outcomes Due to Genes Linked to Pregnancy

According to a study conducted recently at Memorial Sloan Kettering (MSK) Cancer Center, lung cancer co-opts some genes usually involved in helping fetuses to grow. The lung cancer leverages these genes to evade the immune system of the patient. The researchers found that because of this, women in whom these genes were activated tended to have poorer outcomes. This analysis suggests that targeting those genes could have a beneficial effect of improving the clinical outcomes of females diagnosed with lung cancer. The researchers presented their findings at this year’s annual meeting of the American Association of Cancer Research. Jung Hun,…

FridayMay 02, 2025 10:00 am

Data Shows When Hospitals Exit MA Plans, Enrollees Also Leave

For a variety of reasons, hospitals can disagree with Medicare Advantage insurance providers and they part ways. When a hospital cancels or fails to renew its contract with a health insurer, the patients who had coverage with that insurer often have to choose between staying with that insurer and getting care from the shrinking network of providers or ditch the MA plan. Reports indicate that thousands of patients ditch MA plans once the health insurer and hospital fail to continue their relationship. To understand why MA plan holders end up switching insurers or reverting to the government-run Medicare, consider an…

ThursdayMay 01, 2025 10:00 am

Bacterial Meningitis Can Now Be Rapidly Diagnosed with New Test

A team of researchers based at the Amsterdam University Medical Center (UMC) have come up with a new test that can diagnose bacterial meningitis rapidly and with a high degree of accuracy. The test is conducted on cerebrospinal fluid and levels of a protein called CRP are measured. This same protein is also currently relied upon when diagnosing many other bacterial infections. The UMC team found that high CRP levels in cerebrospinal fluid are a highly reliable pointer to the presence of bacterial meningitis. At the moment, treatment for bacterial meningitis is often delayed because a lot of time passes…

ThursdayMay 01, 2025 9:45 am

Soligenix Inc. (NASDAQ: SNGX) HyBryte(TM) Paves Way for Breakthrough Treatment for Rare Skin Cancer

The global rare disease treatment market was estimated at $195.2 billion in 2024 and is anticipated to expand at a CAGR of 11.6% by 2030. SNGX’s HyBryte(TM) has demonstrated positive results in a study testing its use for patients with early-stage CTCL. HyBryte(TM) is a novel therapy based on photodynamic therapy, which combines light and a photosensitizer to target and destroy cancer cells. The development of treatments for rare diseases remains one of the most pressing challenges in modern medicine. Despite significant advancements in healthcare, many rare diseases still have no approved treatments, and patients often face grim prospects. The…

WednesdayApr 30, 2025 10:30 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Committed to Advancing Cancer Care with Innovative RTNova Platform Research

Cancer statistics underscore the urgency of ongoing cancer research and the need for more effective cancer treatments. Calidi Biotherapeutics has announced preclinical results for its RTNova platform, a breakthrough in the delivery of transient gene therapy payloads to targeted tumors. The trials show an ability to deliver therapeutic payloads with precision while simultaneously attacking tumors. Cancer remains one of the deadliest diseases worldwide. Globally, the World Health Organization reports that the number of deaths will surpass 9.7 million in 2024, with a projected 20 million new cancer cases diagnosed; WHO also noted that it anticipates the cancer burden increasing an estimated 77% by…

WednesdayApr 30, 2025 10:00 am

AI Can Predict the Recurrence of Brain Tumors in Kids, Study Finds

A team of researchers has leveraged a technique called temporal learning to train an AI system to predict the likelihood of brain cancer recurring in kids diagnosed with gliomas. This AI model uses the magnetic resonance images periodically captured after the kids have received treatment for the gliomas. The study’s findings, based on analyzing multiple images, indicate that the AI model can produce predictions that are 89% accurate when compared to predictions made on the basis of just one image that have an accuracy rate of 50%., no different from flipping a coin. This approach, which looks for subtle changes…

WednesdayApr 30, 2025 9:45 am

Nutriband Inc. (NASDAQ: NTRB) Leadership Team: Driving Innovation and Shaping the Future of Global Healthcare

Sheridan was recently named as a finalist for the 2025 EY Entrepreneur of the Year Awards The CEO’s international perspective and expertise were further validated when he was featured in a recent BBC News article Chairman Serguei Melnik also participated in a market interview where he spoke about Nutriband’s mission, achievements and plans for the future Nutriband (NASDAQ: NTRB) is earning widespread recognition for the board’s leadership, expertise and innovation across a variety of platforms. Sheridan has recently been acknowledged in several high-profile ways that affirm his growing influence as a respected professional in the healthcare and business sectors. From being…

TuesdayApr 29, 2025 9:00 am

Calidi Biotherapeutics Inc. (NYSE American: CLDI) Reports Innovative RTNova Platform Research, Exemplifies Pivotal Role of Research

“Research on the treatment of cancer is fundamental to improving outcomes for all patients affected by the disease,” reports the National Cancer Institute. CLDI is reporting preclinical results for its systemic RTNova platform, which has successfully delivered transient gene therapy payloads to targeted tumors. “With this breakthrough, we can use our platform to develop multiple assets for various indications,” says CEO. Cancer remains one of the most formidable health challenges worldwide, necessitating relentless research to uncover effective treatments. Continuous scientific inquiry has led to groundbreaking therapies, offering hope to millions. A recent development in this arena is Calidi Biotherapeutics’ (NYSE…